The nation of Zimbabwe has rejected a substantial American health deal valued at $367m (£272m) spanning five years due to the United States' insistence on confidential biological samples.
This move came to light following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the deal was "skewed".
An official representative has since stated that the United States was requesting health data for scientific study and commercial purposes but was unwilling to share the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate task of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had furnished more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged continued negotiations to find a deal agreeable to all parties so the nation's vital HIV treatment initiative can be sustained.
Wider Context
This development comes after a comparable case in neighbouring Kenya, where a court blocked a related health funding agreement following concerns were raised about the security of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
USAID had overseen aid for the American government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to boost transparency and responsibility.
According to statements, Sixteen African countries have to date signed these new agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this partnership would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million currently on antiretroviral therapy through US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, with no corresponding guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"In essence, our country would provide the raw materials for scientific discovery with no assurance that the end products would be accessible to our population should a new disease outbreak arise."
National Interest and International Frameworks
Mangwana further noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting systems previously established through the international health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to deal with future global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its information, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to create them."
These objections over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how future co-operation might be structured in a manner that honours the independence and dignity of each country."
Health Experts Reaction
A leading public health body stated it understood the government's concerns, but recommended that negotiations must proceed considering a large portion of the country's HIV programmes relied on foreign aid.
"If technical issues arise, including those involving information security or agreement terms, these can often be addressed via detailed discussion and negotiated safeguards," the group added.
The situation highlights the ongoing challenges between accepting much-needed foreign assistance and safeguarding a country's data in an increasingly data-driven world.